Invivyd Inc (IVVD)
2.40
-0.04
(-1.64%)
USD |
NASDAQ |
May 02, 10:59
Invivyd Cash from Operations (TTM): -173.16M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -173.16M |
| September 30, 2023 | -161.33M |
| June 30, 2023 | -182.12M |
| March 31, 2023 | -202.12M |
| December 31, 2022 | -219.99M |
| Date | Value |
|---|---|
| September 30, 2022 | -245.80M |
| June 30, 2022 | -243.87M |
| March 31, 2022 | -220.04M |
| December 31, 2021 | -184.74M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-245.80M
Minimum
Sep 2022
-161.33M
Maximum
Sep 2023
-203.68M
Average
-202.12M
Median
Mar 2023
Cash from Operations (TTM) Benchmarks
| Vanda Pharmaceuticals Inc | 12.80M |
| Ardelyx Inc | -89.72M |
| Viking Therapeutics Inc | -54.87M |
| Stoke Therapeutics Inc | -81.07M |
| MAIA Biotechnology Inc | -13.07M |